Clarity Pharmaceuticals Secures Large-Scale Copper-64 Supply from Theragenics
Clarity Pharmaceuticals has signed a significant manufacturing supply agreement with Theragenics to produce copper-64, a key isotope for its upcoming prostate cancer diagnostic, Cu-SAR-bisPSMA. This deal strengthens Clarity’s US supply network ahead of anticipated FDA approval and commercial launch.
- Large-scale copper-64 supply agreement signed with Theragenics
- Theragenics to produce copper-64 at Atlanta facility with 14 cyclotrons
- Supports commercial launch of Cu-SAR-bisPSMA after Phase III trials and FDA approval
- Enhances Clarity’s US supply network alongside existing agreements
- Copper-64’s longer half-life offers logistical advantages over current isotopes
Strategic Supply Partnership
Clarity Pharmaceuticals (ASX:CU6), a clinical-stage radiopharmaceutical company focused on cancer diagnostics, has taken a major step towards commercialising its novel prostate cancer imaging agent, Cu-SAR-bisPSMA. The company announced a large-scale Manufacturing Supply Agreement with Theragenics, a US-based medical solutions provider, to produce copper-64 at Theragenics’ extensive Atlanta facility.
This agreement is pivotal as it aligns with Clarity’s plans to launch Cu-SAR-bisPSMA following the successful completion of its Phase III registrational trials, AMPLIFY and CLARIFY, and subsequent FDA New Drug Application approval. Theragenics brings decades of experience in radiometal production, operating a fleet of 14 cyclotrons capable of producing substantial volumes of copper-64 daily.
Meeting Anticipated Demand
Theragenics’ facility can produce approximately 100 curies of copper-64 per day per cyclotron, translating to around 2,000 patient doses daily. This capacity significantly bolsters Clarity’s existing supply agreements with other US manufacturers, SpectronRx and Nusano, creating a robust and geographically diverse supply network. This network is designed to meet the expected commercial demand for Cu-SAR-bisPSMA across multiple oncology indications.
The longer half-life of copper-64, 12.7 hours compared to less than 2 hours for commonly used isotopes like gallium-68 and fluorine-18, provides a logistical advantage. It allows for a shelf life of up to 48 hours, enabling more flexible scheduling and broader distribution without the inefficiencies and costs associated with short-lived isotopes.
Industry and Clinical Momentum
Theragenics’ CEO Mark Pugh highlighted the company’s excitement about the partnership, noting their existing commercial presence in prostate cancer and the promising data Clarity has generated. Clarity’s Executive Chairperson, Dr Alan Taylor, emphasised the momentum from recent clinical data and regulatory Fast Track Designations, underscoring the importance of a secure and scalable manufacturing strategy ahead of commercialisation.
Clarity’s approach aims to revolutionise radiodiagnostics by improving access and efficiency, reducing waste, and enhancing profitability. The partnership with Theragenics is a critical component of this strategy, leveraging Theragenics’ manufacturing expertise and infrastructure to ensure reliable supply as Clarity prepares for market entry.
Looking Ahead
While Cu-SAR-bisPSMA remains unregistered and pending FDA approval, this supply agreement signals Clarity’s confidence in the product’s potential and readiness to scale. The deal also reflects broader trends in radiopharmaceuticals, where longer-lived isotopes like copper-64 may reshape diagnostic imaging logistics and economics.
Investors and industry watchers will be keen to monitor the progress of Clarity’s Phase III trials and regulatory milestones, as well as how this expanded manufacturing capacity translates into commercial uptake in the competitive prostate cancer diagnostic market.
Bottom Line?
Clarity’s expanded copper-64 supply network positions it well for a scalable commercial launch, but regulatory approval remains the critical next hurdle.
Questions in the middle?
- When will Clarity receive FDA approval for Cu-SAR-bisPSMA?
- How will Clarity’s copper-64 supply agreements impact pricing and market penetration?
- What competitive responses might emerge from other PSMA PET diagnostic providers?
